Aclaris Therapeutics reports Phase 1b proof-of-concept win for ATI-052
Aclaris Therapeutics has announced positive primary analysis results from two Phase 1b proof-of-concept trials of ATI-052, its investigational anti-TSLP/IL-4Rα bispecific antibody, in atopic dermatitis and asthma. Both studies met their primary objective of demonstrating a favourable safety profile, and both showed what the Wayne, Pennsylvania-based company described as rapid, broad clinical responses across heterogeneous patient populations.
The company said it will now prioritise ATI-052's Phase 2b development in eosinophilic oesophagitis, with a trial start targeted for early next year. Chief executive Neal Walker said the results support ATI-052 as "a potent, broadly acting compound with potential best-in-class activity," though the company acknowledged the small trial sizes and the need for larger, controlled studies.
Atopic dermatitis results
The randomised, double-blind, placebo-controlled AD trial enrolled 14 patients with severe atopic dermatitis, of whom 78% in the active per-protocol arm had the highest baseline severity score. Patients received five weekly doses of 480 mg ATI-052. By day 57, the active arm showed a 45% placebo-adjusted mean reduction in the Eczema Area and Severity Index score, with an absolute improvement of 58% versus 13% in the placebo arm. On the itch scale, patients reported a 43% placebo-adjusted improvement in peak pruritus at day 57, with itch relief emerging within the first week of treatment.
Pharmacodynamic data added weight to the clinical signal: 95% normalisation of the lesional skin proteome was observed at week 8, with immune protein expression closely resembling non-lesional skin. Investigator Michael Cameron, assistant clinical professor of dermatology at Mount Sinai in New York, said the rapidity and durability of response was consistent with the drug's dual mechanism, noting one longstanding refractory patient maintained benefit months beyond their final dose.
In the asthma cohort of 16 patients with mild-to-moderate disease, a single 480 mg dose produced a 59% mean absolute reduction in fractional exhaled nitric oxide within 15 days, compared with 15% in the placebo arm. Lung function, measured by FEV1, improved by a placebo-adjusted 200 ml at day 15. A post hoc subgroup restricted to patients with FEV1 below 80% at baseline showed a 350 ml absolute improvement, a figure that Leicester respiratory physician Chris Brightling described as "at least as good if not improving on those seen by comparator compounds."
Market context and competitive read
The bispecific antibody field in atopic disease is intensifying. Dupilumab, the approved IL-4Rα blocker from Regeneron and Sanofi, remains the market benchmark, but the mechanism of ATI-052 adds upstream TSLP blockade to the same downstream IL-4/IL-13 axis targeted by dupilumab. Astegolimab, AstraZeneca's TSLP-targeting tezepelumab, and Sanofi's itepekimab illustrate that TSLP is now a validated node in respiratory inflammation. Aclaris is positioning ATI-052 as combining both mechanistic layers in one molecule, a thesis the pharmacodynamic proteomics data appear to support, though the claim of best-in-class potency will require head-to-head data to stand firm with regulators and prescribers.
Notably, no conjunctivitis was observed in either trial, a meaningful signal given that conjunctivitis is a recognised adverse effect associated with IL-4Rα blockade by dupilumab and has been an area of scrutiny for the class. The company's pivot to eosinophilic oesophagitis as the lead indication reflects both scientific rationale, the Th2-driven pathology of EoE sits squarely within ATI-052's proposed mechanism, and commercial logic: EoE is a less crowded field than moderate-to-severe AD or asthma, and a focused Phase 2b may offer a faster path to a registrational dataset. Investors and analysts will watch closely for disclosed trial design details and any guidance on partnership interest as the programme advances.